非小细胞肺癌软脑膜转移的靶向治疗——不断变化的治疗模式
Targeted therapy for leptomeningeal metastases in non-small cell lung cancer - Changing treatment paradigms.
作者信息
Kumar Shah Binay, Pak Isaac, Budhathoki Nibash, Buker Kayla
机构信息
Binaytara Foundation, Bellingham, WA 98226, USA.
Cancer Center, PeaceHealth United General Hospital, Sedro Woolley, WA 98284, USA.
出版信息
Chin J Cancer Res. 2017 Dec;29(6):535-542. doi: 10.21147/j.issn.1000-9604.2017.06.08.
Abstract
Leptomeningeal metastasis is an uncommon but serious complication in patients with advanced cancers. Leptomeningeal metastasis is diagnosed in approximately 5% of the patients, most commonly among patients with cancers of breast and lung, melanoma, and gastrointestinal malignancies. Treatment goal is to improve survival and quality of the patients. Use of targeted therapies and immunotherapy has led to improved survival of patients with non-small cell lung cancer (NSCLC). In this article, we review emerging data on use of mutation-specific agents and immunotherapy in the treatment of leptomeningeal metastasis among patients with NSCLC.
摘要
软脑膜转移是晚期癌症患者中一种罕见但严重的并发症。约5%的患者会被诊断为软脑膜转移，最常见于乳腺癌、肺癌、黑色素瘤和胃肠道恶性肿瘤患者中。治疗目标是提高患者的生存率和生活质量。靶向治疗和免疫治疗的应用已使非小细胞肺癌（NSCLC）患者的生存率得到提高。在本文中，我们综述了关于使用突变特异性药物和免疫治疗NSCLC患者软脑膜转移的最新数据。
相似文献
1
Targeted therapy for leptomeningeal metastases in non-small cell lung cancer - Changing treatment paradigms.非小细胞肺癌软脑膜转移的靶向治疗——不断变化的治疗模式
Chin J Cancer Res. 2017 Dec;29(6):535-542. doi: 10.21147/j.issn.1000-9604.2017.06.08.
2
Leptomeningeal metastases of solid cancer.实体癌的软脑膜转移
Curr Opin Neurol. 2016 Dec;29(6):797-805. doi: 10.1097/WCO.0000000000000393.
3
Leptomeningeal metastases in non-small-cell lung cancer.非小细胞肺癌的脑膜转移。
Lancet Oncol. 2018 Jan;19(1):e43-e55. doi: 10.1016/S1470-2045(17)30689-7.
4
The Underlying Biology and Therapeutic Vulnerabilities of Leptomeningeal Metastases in Adult Solid Cancers.成人实体癌软脑膜转移的潜在生物学特性及治疗脆弱性
Cancers (Basel). 2021 Feb 10;13(4):732. doi: 10.3390/cancers13040732.
5
The Riddle of the Sphinx: Progress in Leptomeningeal Metastasis of Non-Small Cell Lung Cancer.斯芬克斯之谜：非小细胞肺癌软脑膜转移的研究进展
Clin Med Insights Oncol. 2023 Oct 30;17:11795549231205206. doi: 10.1177/11795549231205206. eCollection 2023.
6
How we treat patients with leptomeningeal metastases.我们如何治疗软脑膜转移患者。
ESMO Open. 2019 May 21;4(Suppl 2):e000507. doi: 10.1136/esmoopen-2019-000507. eCollection 2019.
7
Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis.全脑放疗不能改善 EGFR 突变型 NSCLC 伴软脑膜转移患者的总生存期。
Radiat Oncol. 2019 Sep 14;14(1):168. doi: 10.1186/s13014-019-1376-z.
8
Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.表皮生长因子受体（EGFR）突变的非小细胞肺癌合并软脑膜转移患者的治疗与生存情况：一项回顾性队列分析
Lung Cancer. 2015 Sep;89(3):255-61. doi: 10.1016/j.lungcan.2015.05.023. Epub 2015 Jun 6.
9
Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer.厄洛替尼联合贝伐单抗作为表皮生长因子受体（EGFR）突变阳性非小细胞肺癌软脑膜转移的有效治疗方法。
Lung Cancer. 2016 Sep;99:120-2. doi: 10.1016/j.lungcan.2016.07.008. Epub 2016 Jul 6.
10
Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells.通过对脑脊液循环肿瘤细胞进行下一代测序检测 NSCLC 脑膜转移中的驱动和耐药突变。
Clin Cancer Res. 2017 Sep 15;23(18):5480-5488. doi: 10.1158/1078-0432.CCR-17-0047. Epub 2017 Jun 12.
引用本文的文献
1
Combination of immunotherapy and whole-brain radiotherapy on prognosis of patients with multiple brain metastases: A retrospective cohort study.免疫疗法与全脑放疗联合应用对多发脑转移患者预后的影响：一项回顾性队列研究。
Open Life Sci. 2025 Sep 1;20(1):20251102. doi: 10.1515/biol-2025-1102. eCollection 2025.
2
GTPBP4: A New Therapeutic Target Gene Promotes Tumor Progression in Non-Small Cell Lung Cancer via EMT.GTPBP4：一种新的治疗靶点基因通过上皮-间质转化促进非小细胞肺癌的肿瘤进展。
J Oncol. 2022 Nov 11;2022:2164897. doi: 10.1155/2022/2164897. eCollection 2022.
3
Long noncoding RNA POU6F2-AS1 regulates lung cancer aggressiveness through sponging miR-34c-5p to modulate KCNJ4 expression.长链非编码RNA POU6F2-AS1通过吸附miR-34c-5p调节KCNJ4表达来调控肺癌侵袭性。
Genet Mol Biol. 2021 May 14;44(2):e20200050. doi: 10.1590/1678-4685-GMB-2020-0050. eCollection 2021.
4
Leptomeningeal Carcinomatosis in Epithelial Ovarian Cancer: A Diagnostic Challenge.上皮性卵巢癌的软脑膜癌病：一项诊断挑战。
Cureus. 2021 Apr 12;13(4):e14440. doi: 10.7759/cureus.14440.
5
Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases.立体定向放射外科或全脑放射治疗与免疫疗法联合用于治疗脑转移瘤。
Chin J Cancer Res. 2020 Aug;32(4):448-466. doi: 10.21147/j.issn.1000-9604.2020.04.03.
6
Classification of Leptomeningeal Metastases from Solid Organ Malignancies and Clinical Outcomes: Series from a Cancer Research Centre.实体器官恶性肿瘤软脑膜转移的分类及临床结局：来自癌症研究中心的系列研究
Indian J Surg Oncol. 2020 Jun;11(2):308-312. doi: 10.1007/s13193-020-01071-0. Epub 2020 Apr 17.
7
Identification of Cerebrospinal Fluid MicroRNAs Associated With Leptomeningeal Metastasis From Lung Adenocarcinoma.鉴定与肺腺癌软脑膜转移相关的脑脊液微小RNA
Front Oncol. 2020 Apr 3;10:387. doi: 10.3389/fonc.2020.00387. eCollection 2020.
8
Prognostic implications of epidermal growth factor receptor variant III expression and nuclear translocation in Chinese human gliomas.表皮生长因子受体III型变体表达及核转位在中国人类胶质瘤中的预后意义
Chin J Cancer Res. 2019 Feb;31(1):188-202. doi: 10.21147/j.issn.1000-9604.2019.01.14.
9
An Acquired Epidermal Growth Factor Receptor T790M Mutation after the Addition of Bevacizumab to Preceding Erlotinib Monotherapy in a Lung Cancer Patient with Leptomeningeal Metastases.一名肺癌软脑膜转移患者在先前厄洛替尼单药治疗基础上加用贝伐单抗后出现获得性表皮生长因子受体T790M突变。
Intern Med. 2018 Dec 1;57(23):3423-3427. doi: 10.2169/internalmedicine.1062-18. Epub 2018 Aug 10.
本文引用的文献
1
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.辅助达拉非尼联合曲美替尼治疗 BRAF 突变型 III 期黑色素瘤。
N Engl J Med. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. Epub 2017 Sep 10.
2
Treatment options for EGFR mutant NSCLC with CNS involvement-Can patients BLOOM with the use of next generation EGFR TKIs?伴有中枢神经系统受累的EGFR突变型非小细胞肺癌的治疗选择——使用新一代EGFR酪氨酸激酶抑制剂患者能“绽放”吗？
Lung Cancer. 2017 Jun;108:29-37. doi: 10.1016/j.lungcan.2017.02.012. Epub 2017 Feb 22.
3
Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib.厄洛替尼治疗失败后贝伐单抗与厄洛替尼联合治疗柔脑膜癌病的疗效
Anticancer Drugs. 2017 Jun;28(5):565-567. doi: 10.1097/CAD.0000000000000489.
4
Highly sensitive detection of a HER2 12-base pair duplicated insertion mutation in lung cancer using the Eprobe-PCR method.使用Eprobe-PCR方法对肺癌中HER2 12碱基对重复插入突变进行高灵敏度检测。
PLoS One. 2017 Feb 2;12(2):e0171225. doi: 10.1371/journal.pone.0171225. eCollection 2017.
5
A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1).非小细胞肺癌靶向治疗的新前沿：帕博利珠单抗抑制程序性细胞死亡1（PD-1）的临床疗效
Expert Rev Anticancer Ther. 2017 Mar;17(3):199-201. doi: 10.1080/14737140.2017.1286986. Epub 2017 Feb 8.
6
Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era.非小细胞肺癌患者的脑膜转移癌：个体化治疗时代的持续挑战。
Cancer Treat Rev. 2017 Feb;53:128-137. doi: 10.1016/j.ctrv.2016.12.006. Epub 2016 Dec 30.
7
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.奥希替尼或铂类培美曲塞用于治疗表皮生长因子受体T790M阳性肺癌
N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6.
8
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.布加替尼在间变性淋巴瘤激酶重排的非小细胞肺癌和其他恶性肿瘤中的活性和安全性：一项单臂、开放标签、1/2 期试验。
Lancet Oncol. 2016 Dec;17(12):1683-1696. doi: 10.1016/S1470-2045(16)30392-8. Epub 2016 Nov 8.
9
Drug resistance in ALK-positiveNon-small cell lungcancer patients.ALK 阳性非小细胞肺癌患者的耐药性。
Semin Cell Dev Biol. 2017 Apr;64:150-157. doi: 10.1016/j.semcdb.2016.09.016. Epub 2016 Sep 29.
10
Targeted Therapies for Brain Metastases from Breast Cancer.乳腺癌脑转移的靶向治疗
Int J Mol Sci. 2016 Sep 13;17(9):1543. doi: 10.3390/ijms17091543.
Zotero 插件